This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
One of the most studied repair peptides in existence. BPC-157 accelerates healing in tendons, muscles, joints, and the gut — through mechanisms that no other peptide replicates.
BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide sequence first isolated by Dr. Predrag Sikiric in 1993 from a protective protein found in human gastric juice. It was originally studied for its role in mucosal defense — the ability of the stomach lining to protect and repair itself under stress.
What researchers discovered is that BPC-157's regenerative effects extend far beyond the gut. It activates multiple healing pathways simultaneously: it triggers the FAK-paxillin signaling cascade to accelerate tendon fibroblast proliferation, initiates VEGFR2-driven angiogenesis to grow new blood vessels into damaged tissue, and enhances growth hormone receptor expression in fibroblasts to increase collagen synthesis.
The result is faster, more complete healing in tissues that normally repair slowly — tendons, ligaments, cartilage, and muscle — while also providing protective effects on the gastrointestinal lining, liver, and vascular system.
BPC-157 has been studied in hundreds of animal model experiments demonstrating consistent tissue repair effects. One human case series reported symptom reduction in over 90% of patients following intra-articular administration. Large-scale randomized controlled trials in humans are ongoing. All information on this page is for research purposes.
Activates the FAK-paxillin pathway to accelerate tendon fibroblast migration and proliferation. Studies show significantly faster tendon-to-bone healing with improved biomechanical strength compared to untreated controls.
Triggers VEGFR2 activation to grow new blood vessels into avascular (blood-poor) tissues like tendons and ligaments — the primary reason these tissues heal so slowly without intervention.
Maintains intestinal barrier integrity by regulating tight junction proteins (ZO-1). Counteracts NSAID-induced gastric lesions and liver enzyme spikes — even during continued NSAID use.
Enhances growth hormone receptor expression in fibroblasts, increasing collagen synthesis. Demonstrated anti-inflammatory effects reduce recovery time from muscle tears and contusions.
Modulates nitric oxide and dopamine systems. Research shows potential for neuroprotective effects including recovery from traumatic brain injury and spinal cord lesions in animal models.
Hepatoprotective effects observed across multiple models — protects liver tissue from toxin-induced damage. Vascular integrity is maintained through nitric oxide modulation.
BPC-157 is administered either subcutaneously (SC) or intramuscularly (IM), with injection sites typically near the area of injury for localized effect. Unlike most peptides, BPC-157 is stable in the stomach's acidic environment, which makes oral administration viable — though injectable routes are preferred for musculoskeletal applications.
| Parameter | Standard Range | Notes |
|---|---|---|
| Dose per injection | 200 – 500 mcg | Start at 250 mcg to assess individual response |
| Frequency | Once or twice daily | BID dosing common for acute injury protocols |
| Duration | 4 – 12 weeks | Acute injuries: 4-6 wk; chronic conditions: 8-12 wk |
| Route | SC or IM | Inject near injury site for localized effect |
| Oral alternative | 500 mcg – 1 mg | For gut/systemic use; less effective for musculoskeletal |
| Storage (lyophilized) | Refrigerated or frozen | Reconstitute with bacteriostatic water; use within 30 days |
Reconstitution: Add bacteriostatic water slowly down the inside of the vial. Do not shake — swirl gently. Standard reconstitution: 2 mL bac water per vial for easy dosing math. See our Supplies Guide for everything needed.
BPC-157's research base is one of the deepest in the peptide field, with published studies dating to the early 1990s. The primary body of evidence comes from animal models — rodent and rabbit studies across dozens of institutions — with a growing number of human case series and small cohort studies.
Multiple studies confirm that BPC-157 activates the FAK-paxillin signaling cascade in tendon fibroblasts, dramatically increasing their migration rate and proliferation. The result is faster collagen synthesis and measurably improved tensile strength at the healing site versus untreated controls.
BPC-157 maintains intestinal barrier integrity through tight junction protein regulation (ZO-1). In NSAID-induced gastric lesion models, BPC-157 prevented liver enzyme spikes and healed mucosal damage — even when NSAID use continued. This protective mechanism is distinct from proton pump inhibitors.
VEGFR2 activation by BPC-157 drives new vessel formation into tissue that normally has poor blood supply — the core reason tendons and ligaments are notoriously slow-healing. This vascular recruitment accelerates delivery of growth factors and immune cells to the injury site.
Pilot data (Lee & Burgess, 2025) reported no significant adverse effects on major organs at doses studied. Mild effects include transient local irritation at injection site, occasional dizziness, and mild nausea. No organ toxicity signals observed across the published animal literature.
BPC-157 is frequently combined with other peptides for enhanced recovery. These pairings are supported by both research and clinical practice.
Complete your health intake. A licensed physician reviews your case within 24 hours and determines if you're a candidate.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.